drugset / Trial / NCT04418648
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
Phase 2
Terminated
170 enrolled
Sun Yat-sen University
Guangzhou Panyu Central Hospital · collabThe First Affiliated Hospital of Guangzhou Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The phase II, randomised study is to explore the efficacy and safety of toripalimab as consolidation therapy in patients with limited-stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy
Timeline
- Start
- 2020-06-01
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
Outcome
Outcome not reported
Stopped: “Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |